The Impact of Minimal Residual Disease in Acute Lymphoblastic Leukemia

June 16, 2017

[Click here to enlarge.] 

Presentation

Click Here


 

Topics Covered

We invite you to learn more about:

  • ​Current treatment options for patients living with ALL
  • The impact of minimal residual disease (MRD)
  • Clinical trials and emerging therapies for ALL treatment
  • The importance of open communication with your healthcare team to promote a better quality of life


 

Speaker

Daniel J. DeAngelo, M.D., Ph.D.
Adult Leukemia Program
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
 

Program Support

Support for this program provided by 


 

For any questions or comments about this program, please email feedback@LLS.org.

< Back to Webcasts